Fiche publication
Date publication
mai 2017
Journal
Journal of hematology & oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BENSOUSSAN Danièle
,
Pr DE CARVALHO BITTENCOURT Marcelo
,
Dr JEULIN Hélène
,
Pr DECOT Véronique
,
Dr D'AVENI-PINEY Maud
,
Dr POCHON Cécile
,
Dr REPPEL Loïc
Tous les auteurs :
Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H, Dalle JH, Pochon C, D'aveni M, Bruno B, Paillard C, Vigouroux S, Jubert C, Ceballos P, Marie-Cardine A, Galambrun C, Cholle C, Clerc Urmes I, Petitpain N, De Carvalho Bittencourt M, Decot V, Reppel L, Salmon A, Clement L, Bensoussan D
Lien Pubmed
Résumé
Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threatening complications: graft versus host disease (GVHD) and infections especially viral infections refractory to antiviral drugs. Adoptive transfer of virus-specific T cells is becoming an alternative treatment for infections following HSCT. We report here the results of a phase I/II multicenter study which includes a series of adenovirus-specific T cell (ADV-VST) infusion either from the HSCT donor or from a third party haploidentical donor for patients transplanted with umbilical cord blood (UCB).
Mots clés
Adenovirus-specific T cells, Allogeneic stem cell transplantation, Interferon-γ-based immunomagnetic isolation, Third party haploidentical donor, Umbilical cord blood transplantation
Référence
J Hematol Oncol. 2017 May;10(1):102
